sanorg 34006 profile

idraparinux: a synthetic analogue of the pentasaccharide sequence in heparins [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3083444
MeSH ID	M0291233

Synonym
idraparinux sodium [usan:inn]
methyl o-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuronosyl-(1-4)-2,3,6-tri-o-sulfo-alpha-d-glucopyranosid
unii-h84ixp29fn
149920-56-9
alpha-d-glucopyranoside, methyl o-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuranosyl-(1-4)-, 2,3,6-tris(hy
sanorg34006
h84ixp29fn ,
s-o-34006
org-34006
idraparinux sodium
sanorg-34006
org 34006
sanorg 34006
idraparinux
idraparinux sodium (usan)
D10471
idraparinux sodium [inn]
idraparinux sodium [who-dd]
idraparinux nonasodium salt [mi]
idraparinux sodium [mart.]
methyl (sodium 2,3,4-tri-o-methyl-6-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium 2,3-di-o-methyl-.beta.-d-glucopyranosylurate)-(1->4)-(trisodium 2,3,6-tri-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium -2,3-di-o-methyl-.alpha.-l-idopyranosyl
idraparinux sodium [usan]
Q3147909

Research Excerpts

Overview

SANORG 34006 is a new sulfated pentasaccharide obtained by chemical synthesis.

Excerpt	Reference	Relevance
"SANORG 34006 is a new sulfated pentasaccharide obtained by chemical synthesis. "	( Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Bernat, A; Hérault, JP; Herbert, JM; Hoffmann, P; Lormeau, JC; Meuleman, DG; Petitou, M; van Amsterdam, RG; van Boeckel, C, 1998)	2

Toxicity

Excerpt	Reference	Relevance
"5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism."	( Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Brandolin, B; Perlati, M; Prandoni, P; Spiezia, L; Tormene, D, 2008)	0.35

Pharmacokinetics

Excerpt	Reference	Relevance
"To characterize the population pharmacokinetic profile of idraparinux in patients enrolled in van Gogh and Amadeus Phase III clinical trials."	( The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Dubruc, C; Sanderink, GJ; Trellu, M; Veyrat-Follet, C; Vivier, N, 2009)	0.35
" A population pharmacokinetic model was developed using data from 704 patients with acute deep-vein thrombosis or pulmonary embolism, 1310 patients suffering from atrial fibrillation, and 40 healthy subjects."	( The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Dubruc, C; Sanderink, GJ; Trellu, M; Veyrat-Follet, C; Vivier, N, 2009)	0.35

Bioavailability

Excerpt	Reference	Relevance
"9 hours in baboons), and revealed an SC bioavailability near 100%."	( Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Bernat, A; Hérault, JP; Herbert, JM; Hoffmann, P; Lormeau, JC; Meuleman, DG; Petitou, M; van Amsterdam, RG; van Boeckel, C, 1998)	0.56
" Ex vivo, after intravenous administration to rats, SSR126517E produced a potent and long-lasting anti-FXa effect comparable to that obtained with idraparinux; as with idraparinux, the subcutaneous bioavailability was 100%."	( Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. Bono, F; Duchaussoy, P; Herault, JP; Herbert, JM; Millet, L; Petitou, M; Savi, P; Schaeffer, P, 2008)	0.35
"A three-compartment model best described idraparinux pharmacokinetics, with interindividual variability on clearance, central volume of distribution, and absorption rate constant; residual variability was low."	( The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Dubruc, C; Sanderink, GJ; Trellu, M; Veyrat-Follet, C; Vivier, N, 2009)	0.35

Dosage Studied

Excerpt	Relevance	Reference
" Moreover, ximelagatran has rapid onset and offset of action, fixed oral dosing without the need for anticoagulation monitoring, low potential for food and drug interactions, and a therapeutic margin wider than that of warfarin."	( New possibilities in anticoagulant management of atrial fibrillation. Waldo, AL, 2004)	0.32
" Otherwise, they have some important limitations (narrow therapeutic window, highly variable dose-response relationship; limitation by the need of parenteral administration for heparins and the risk of heparin-induced thrombocytopenia) which provide opportunities for new antithrombotic drugs."	( [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]. Falciani, M; Imberti, D; Prisco, D, 2005)	0.33
" Warfarin has an unpredictable pharmacokinetic profile and a variable dose-response relationship that requires frequent coagulation monitoring and dose adjustments to maintain a target intensity that is both safe and effective."	( Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Bounameaux, H; Huisman, MV, 2005)	0.33
" There are numerous drug/drug and drug/food interactions, and there is difficulty in dosing for one-third of patients."	( The new anticoagulants. Money, SR; Stone, WM; Tonnessen, BH, 2007)	0.34
" Less frequent dosing schedules generally improve adherence."	( Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? Cohen, AT; Maillardet, L; Yavin, Y, 2009)	0.35
" These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]."	( New anticoagulants for atrial fibrillation. Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009)	0.35
"Pharmacodynamic parameters reported after single dose in healthy volunteers and after repeated once weekly dosing in patients demonstrated the bioequipotency of idrabiotaparinux and idraparinux based on FXa inhibition."	( Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. Boëlle, E; Cheng, S; Cortez, P; Donat, F; Fau, JB; Paty, I; Sanderink, GJ; Trellu, M, 2013)	0.39

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (2.25)	18.2507
2000's	56 (62.92)	29.6817
2010's	31 (34.83)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	14 (15.73%)	5.53%
Reviews	42 (47.19%)	6.00%
Case Studies	1 (1.12%)	4.05%
Observational	0 (0.00%)	0.25%
Other	32 (35.96%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
beta-alanine [no description available]	4.95	4	0	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
glycine [no description available]	3.14	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
dalteparin Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)	4.04	4	0
pentachlorophenol PENTA: structure given in first source	2.4	2	0	aromatic fungicide; chlorophenol; organochlorine pesticide; pentachlorobenzenes	human xenobiotic metabolite
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.67	3	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	5.14	4	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.06	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	6.7	10	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
thiazoles [no description available]	4.37	3	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
galactose aldohexose : A hexose with a (potential) aldehyde group at one end.	2.17	1	0
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	5.14	4	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	2.06	1	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.07	1	0	D-glucuronic acid	algal metabolite
dx 9065a (2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid: structure given in first source	3.8	3	0
6-deoxytalose 6-deoxytalose: RN given refers to (L)-isomer	2.17	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	9.58	9	2	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
dabigatran Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.. dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.	7.49	16	0	aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines	anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor
iduronate Iduronic Acid: Component of dermatan sulfate. Differs in configuration from glucuronic acid only at the C-5 position.. iduronic acid : A member of the class of iduronic acids that is the major uronic acid component of the dermatan sulfate and heparin.. idopyranuronic acid : The pyranose form of iduronic acid.. L-idopyranuronic acid : The L-stereoisomer of idopyranuronic acid.. L-iduronic acid : Any iduronic acid having L-configuration.	2.53	2	0	idopyranuronic acid; L-iduronic acid
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.01	1	0	stilbene
vitamin k semiquinone radical vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.	11.46	13	6
fondaparinux Fondaparinux: Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.. fondaparinux : A synthetic pentasaccharide which, apart from the O-methyl group at the reducing end of the molecule, consists of monomeric sugar units which are identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate.	8.59	29	0	amino sugar; oligosaccharide sulfate; pentasaccharide derivative	anticoagulant
fosbretabulin fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source	2.01	1	0
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	7.94	20	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
napsagatran napsagatran: structure given in first source	2	1	0
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	6.89	11	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
ly517717 LY517717: an oral anticoagulant	3.14	1	0
apixaban [no description available]	6.5	9	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
betrixaban betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source. betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.	4.06	2	0	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.	4.37	3	0	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor
idopyranose L-idose : The L-stereoisomer of idose.. L-idopyranose : The pyranose form of L-idose.	2.17	1	0	L-idose
idrabiotaparinux idrabiotaparinux: a biotinylated form of idraparinux with anticoagulant properties	9.19	7	2
piperidines Piperidines: A family of hexahydropyridines.	2	1	0
acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.	5.33	2	2	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	10.42	17	4	benzenes; hydroxycoumarin; methyl ketone
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	4.02	4	0

Condition	Relationship Strength	Studies	Trials
Recrudescence [description not available]	10.62	11	6
Deep Vein Thrombosis [description not available]	13.07	23	10
Bleeding [description not available]	13.2	25	13
Hemorrhage Bleeding or escape of blood from a vessel.	13.2	25	13
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	13.07	23	10
Thromboembolism, Venous [description not available]	6.63	11	0
Benign Neoplasms [description not available]	6.27	5	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	6.27	5	1
Venous Thromboembolism Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.	6.63	11	0
Embolism, Pulmonary [description not available]	11.15	15	6
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	11.15	15	6
Apoplexy [description not available]	10.3	15	6
Chronic Kidney Diseases [description not available]	3.47	1	1
Auricular Fibrillation [description not available]	11.49	23	7
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	11.49	23	7
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	10.3	15	6
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	3.47	1	1
Cardiovascular Stroke [description not available]	3.03	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	3.03	1	0
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	9.53	18	1
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	3.51	1	1
Embolus [description not available]	3.51	1	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	3.51	1	1
Embolism Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.	3.51	1	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	3.51	1	1
Blood Clot [description not available]	6.26	11	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	6.26	11	0
Bullous Dermatoses [description not available]	2.04	1	0
Thrombopenia [description not available]	2.96	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.96	1	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	3.43	1	1
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	3.43	1	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.06	1	0
Cerebral Ischemia [description not available]	2.99	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.99	1	0
Angiogenesis, Pathologic [description not available]	2.01	1	0
Coagulation Disorders, Blood [description not available]	2.93	1	0
Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.	2.93	1	0
Acute Liver Injury, Drug-Induced [description not available]	2.02	1	0
Heart Disease, Ischemic [description not available]	2.02	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.02	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.02	1	0
Cancer of Lung [description not available]	2.02	1	0
Thoracic Diseases Disorders affecting the organs of the thorax.	2.02	1	0
Hemoptysis Expectoration or spitting of blood originating from any part of the RESPIRATORY TRACT, usually from hemorrhage in the lung parenchyma (PULMONARY ALVEOLI) and the BRONCHIAL ARTERIES.	2.02	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.02	1	0
Cardiac Failure [description not available]	3.35	2	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	3.35	2	0
Postphlebitic Disease [description not available]	3.82	2	0
Autoimmune Thrombocytopenia [description not available]	2.03	1	0
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	2.03	1	0
Community Acquired Infection [description not available]	2.04	1	0
Bacterial Pneumonia [description not available]	2.04	1	0
Bone Fractures [description not available]	2.04	1	0
Coronary Heart Disease [description not available]	2.04	1	0
Diabetes Mellitus, Adult-Onset [description not available]	2.04	1	0
Cardiac Cancer [description not available]	2.04	1	0
Cirrhosis, Liver [description not available]	2.04	1	0
Age-Related Osteoporosis [description not available]	2.04	1	0
Primary Peritonitis [description not available]	2.04	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2.04	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.04	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.04	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.04	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.04	1	0
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	2.04	1	0
Fractures, Bone Breaks in bones.	2.04	1	0
Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.	2.96	1	0

sanorg 34006

Description

Cross-References

Synonyms (23)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (89)

Study Types

sanorg 34006

Description

Cross-References

Synonyms (23)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (89)

Study Types

Related Drugs (35)

Related Conditions (68)